{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:05:16Z","timestamp":1791223516615,"version":"4.1.0"},"reference-count":47,"publisher":"Portland Press Ltd.","issue":"20","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Osteogenic factors, such as osteoprotegerin (OPG), are protective against vascular calcification. However, OPG is also positively associated with cardiovascular damage, particularly in pulmonary hypertension, possibly through processes beyond effects on calcification. In the present study, we focused on calcification-independent vascular effects of OPG through activation of syndecan-1 and NADPH oxidases (Noxs) 1 and 4. Isolated resistance arteries from Wistar\u2013Kyoto (WKY) rats, exposed to exogenous OPG, studied by myography exhibited endothelial and smooth muscle dysfunction. OPG decreased nitric oxide (NO) production, eNOS activation and increased reactive oxygen species (ROS) production in endothelial cells. In VSMCs, OPG increased ROS production, H2O2\/peroxynitrite levels and activation of Rho kinase and myosin light chain. OPG vascular and redox effects were also inhibited by the syndecan-1 inhibitor synstatin (SSNT). Additionally, heparinase and chondroitinase abolished OPG effects on VSMCs-ROS production, confirming syndecan-1 as OPG molecular partner and suggesting that OPG binds to heparan\/chondroitin sulphate chains of syndecan-1. OPG-induced ROS production was abrogated by NoxA1ds (Nox1 inhibitor) and GKT137831 (dual Nox1\/Nox4 inhibitor). Tempol (SOD mimetic) inhibited vascular dysfunction induced by OPG. In addition, we studied arteries from Nox1 and Nox4 knockout (KO) mice. Nox1 and Nox4 KO abrogated OPG-induced vascular dysfunction. Vascular dysfunction elicited by OPG is mediated by a complex signalling cascade involving syndecan-1, Nox1 and Nox4. Our data identify novel molecular mechanisms beyond calcification for OPG, which may underlie vascular injurious effects of osteogenic factors in conditions such as hypertension and\/or diabetes.<\/jats:p>","DOI":"10.1042\/cs20210643","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T22:30:18Z","timestamp":1634769018000},"page":"2429-2444","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Osteoprotegerin regulates vascular function through syndecan-1 and NADPH oxidase-derived reactive oxygen species"],"prefix":"10.1042","volume":"135","author":[{"given":"Rh\u00e9ure","family":"Alves-Lopes","sequence":"first","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-9263","authenticated-orcid":false,"given":"Karla\u00a0Bianca","family":"Neves","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya","family":"Strembitska","sequence":"additional","affiliation":[{"name":"Centre for Integrative Genomics, University of Lausanne, 1015 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam\u00a0P.","family":"Harvey","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie\u00a0Y.","family":"Harvey","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Yusuf","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Haniford","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross\u00a0T.","family":"Hepburn","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dyet","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Beattie","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Haddow","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McAbney","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delyth","family":"Graham","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8658-7994","authenticated-orcid":false,"given":"Augusto\u00a0C.","family":"Montezano","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"2021113011242212800_B1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11906-014-0431-2","article-title":"Angiotensin II and vascular injury","volume":"16","author":"Montezano","year":"2014","journal-title":"Curr. Hypertens. Rep."},{"key":"2021113011242212800_B2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cjca.2016.02.070","article-title":"Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications","volume":"32","author":"Harvey","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"2021113011242212800_B3","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.3109\/07853890.2012.660498","article-title":"Vascular calcification and hypertension: cause and effect","volume":"44","author":"Kalra","year":"2012","journal-title":"Ann. Med."},{"key":"2021113011242212800_B4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1525-139X.2007.00255.x","article-title":"The vascular biology of calcification","volume":"20","author":"Shroff","year":"2007","journal-title":"Semin. Dial."},{"key":"2021113011242212800_B5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/hr.2011.201","article-title":"The balance of fetuin-A and osteoprotegerin is independently associated with diastolic dysfunction in hemodialysis patients","volume":"35","author":"Talib","year":"2012","journal-title":"Hypertens. Res."},{"key":"2021113011242212800_B6","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1093\/ndt\/gfn226","article-title":"The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis","volume":"23","author":"Shroff","year":"2008","journal-title":"Nephrol. Dialysis Transplant."},{"key":"2021113011242212800_B7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0006-291X(02)00137-7","article-title":"A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function","volume":"293","author":"Brandstrom","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113011242212800_B8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.bbrc.2006.06.120","article-title":"Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK","volume":"347","author":"Theoleyre","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113011242212800_B9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.mvr.2008.06.004","article-title":"Role of alphav integrin in osteoprotegerin-induced endothelial cell migration and proliferation","volume":"76","author":"Kobayashi-Sakamoto","year":"2008","journal-title":"Microvasc. Res."},{"key":"2021113011242212800_B10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/wound.2014.0555","article-title":"Syndecan-1 and its expanding list of contacts","volume":"4","author":"Stepp","year":"2015","journal-title":"Adv. Wound Care"},{"key":"2021113011242212800_B11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10456-013-9337-x","article-title":"Mechanistic study of the proangiogenic effect of osteoprotegerin","volume":"16","author":"Benslimane-Ahmim","year":"2013","journal-title":"Angiogenesis"},{"key":"2021113011242212800_B12","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1210\/jc.2004-1895","article-title":"Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes","volume":"90","author":"Mosheimer","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113011242212800_B13","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1161\/CIRCULATIONAHA.105.573709","article-title":"Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice","volume":"112","author":"Matsuno","year":"2005","journal-title":"Circulation"},{"key":"2021113011242212800_B14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1161\/CIRCRESAHA.112.267054","article-title":"Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase","volume":"110","author":"Schroder","year":"2012","journal-title":"Circ. Res."},{"key":"2021113011242212800_B15","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1161\/01.HYP.0000158845.49943.5e","article-title":"Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase","volume":"45","author":"Touyz","year":"2005","journal-title":"Hypertension"},{"key":"2021113011242212800_B16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.107.103192","article-title":"Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension","volume":"51","author":"Yogi","year":"2008","journal-title":"Hypertension"},{"key":"2021113011242212800_B17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1161\/HYPERTENSIONAHA.115.05616","article-title":"Chemerin regulates crosstalk between adipocytes and vascular cells through Nox","volume":"66","author":"Neves","year":"2015","journal-title":"Hypertension"},{"key":"2021113011242212800_B18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1084\/jem.20081278","article-title":"Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor","volume":"206","author":"Beauvais","year":"2009","journal-title":"J. Exp. Med."},{"key":"2021113011242212800_B19","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev."},{"key":"2021113011242212800_B20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000358920","article-title":"Increased calcification in osteoprotegerin-deficient smooth muscle cells: dependence on receptor activator of NF-kappaB ligand and interleukin 6","volume":"51","author":"Callegari","year":"2014","journal-title":"J. Vasc. Res."},{"key":"2021113011242212800_B21","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1161\/01.ATV.0000236428.91125.e6","article-title":"Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-\/- mice","volume":"26","author":"Bennett","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113011242212800_B22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/CIRCULATIONAHA.107.707380","article-title":"Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-\/-) mice","volume":"117","author":"Morony","year":"2008","journal-title":"Circulation"},{"key":"2021113011242212800_B23","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/01.CIR.0000031524.49139.29","article-title":"Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease","volume":"106","author":"Jono","year":"2002","journal-title":"Circulation"},{"key":"2021113011242212800_B24","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1161\/01.CIR.0000127957.43874.BB","article-title":"Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease","volume":"109","author":"Kiechl","year":"2004","journal-title":"Circulation"},{"key":"2021113011242212800_B25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000157629","article-title":"Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients","volume":"29","author":"Nishiura","year":"2009","journal-title":"Am. J. Nephrol."},{"key":"2021113011242212800_B26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1538-7836.2011.04222.x","article-title":"Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study","volume":"9","author":"Vik","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"2021113011242212800_B27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.advms.2016.03.003","article-title":"Osteoprotegerin and osteoprotegerin\/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure","volume":"61","author":"Kuzniewski","year":"2016","journal-title":"Adv. Med. Sci."},{"key":"2021113011242212800_B28","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1182\/blood-2007-01-068395","article-title":"Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo","volume":"110","author":"Zauli","year":"2007","journal-title":"Blood"},{"key":"2021113011242212800_B29","doi-asserted-by":"publisher","first-page":"34927","DOI":"10.1074\/jbc.M112.376814","article-title":"Transmembrane and extracellular domains of syndecan-1 have distinct functions in regulating lung epithelial migration and adhesion","volume":"287","author":"Altemeier","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2021113011242212800_B30","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1038\/s41467-019-13139-9","article-title":"A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension","volume":"10","author":"Arnold","year":"2019","journal-title":"Nat. Commun."},{"key":"2021113011242212800_B31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/hr.2010.201","article-title":"Reactive oxygen species and vascular biology: implications in human hypertension","volume":"34","author":"Touyz","year":"2011","journal-title":"Hypertens. Res."},{"key":"2021113011242212800_B32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.lfs.2017.05.002","article-title":"Vascular dysfunction and fibrosis in stroke-prone spontaneously hypertensive rats: the aldosterone-mineralocorticoid receptor-Nox1 axis","volume":"179","author":"Harvey","year":"2017","journal-title":"Life Sci."},{"key":"2021113011242212800_B33","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1161\/ATVBAHA.116.308929","article-title":"Serotonin signaling through the 5-HT1B receptor and NADPH oxidase 1 in pulmonary arterial hypertension","volume":"37","author":"Hood","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113011242212800_B34","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1161\/HYPERTENSIONAHA.119.13398","article-title":"Leptin restores endothelial function via endothelial PPARgamma-Nox1-mediated mechanisms in a mouse model of congenital generalized lipodystrophy","volume":"74","author":"Bruder-Nascimento","year":"2019","journal-title":"Hypertension"},{"key":"2021113011242212800_B35","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1161\/01.RES.0000054200.44505.AB","article-title":"Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles","volume":"92","author":"Miura","year":"2003","journal-title":"Circ. Res."},{"key":"2021113011242212800_B36","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1093\/eurheartj\/ehv460","article-title":"The NADPH oxidase Nox4 has anti-atherosclerotic functions","volume":"36","author":"Schurmann","year":"2015","journal-title":"Eur. Heart J."},{"key":"2021113011242212800_B37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.freeradbiomed.2015.08.014","article-title":"NOX4-dependent Hydrogen peroxide promotes shear stress-induced SHP2 sulfenylation and eNOS activation","volume":"89","author":"Sanchez-Gomez","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"2021113011242212800_B38","doi-asserted-by":"publisher","first-page":"8737","DOI":"10.1074\/jbc.M111.332494","article-title":"Constitutive NADPH oxidase 4 activity resides in the composition of the B-loop and the penultimate C terminus","volume":"287","author":"von Lohneysen","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2021113011242212800_B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21061994","article-title":"Oxidative stress and mitochondrial abnormalities contribute to decreased endothelial nitric oxide synthase expression and renal disease progression in early experimental polycystic kidney disease","volume":"21","author":"Kahveci","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"2021113011242212800_B40","doi-asserted-by":"publisher","first-page":"L1097","DOI":"10.1152\/ajplung.00480.2019","article-title":"NADPH oxidase mediated endothelial injury in HIV and opioid induced pulmonary arterial hypertension","volume":"318","author":"Agarwal","year":"2020","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2021113011242212800_B41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.clinre.2018.10.004","article-title":"NADPH oxidase 1\/4 inhibition attenuates the portal hypertensive syndrome via modulation of mesenteric angiogenesis and arterial hyporeactivity in rats","volume":"43","author":"Deng","year":"2019","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"2021113011242212800_B42","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/HYPERTENSIONAHA.119.14100","article-title":"Nox (NADPH Oxidase) 1, Nox4, and Nox5 promote vascular permeability and neovascularization in retinopathy","volume":"75","author":"Deliyanti","year":"2020","journal-title":"Hypertension"},{"key":"2021113011242212800_B43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1161\/HYPERTENSIONAHA.118.10824","article-title":"Vascular nox (NADPH oxidase) compartmentalization, protein hyperoxidation, and endoplasmic reticulum stress response in hypertension","volume":"72","author":"Camargo","year":"2018","journal-title":"Hypertension"},{"key":"2021113011242212800_B44","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2353\/ajpath.2008.070395","article-title":"Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension","volume":"172","author":"Lawrie","year":"2008","journal-title":"Am. J. Pathol."},{"key":"2021113011242212800_B45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/21224","article-title":"Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation","volume":"399","author":"Dimmeler","year":"1999","journal-title":"Nature"},{"key":"2021113011242212800_B46","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4161\/cc.5.5.2538","article-title":"Akt1 in endothelial cell and angiogenesis","volume":"5","author":"Somanath","year":"2006","journal-title":"Cell Cycle"},{"key":"2021113011242212800_B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.earlhumdev.2019.06.001","article-title":"Osteoprotegerin and RANKL serum concentrations in neonates of mothers with early-onset pre-eclampsia: comparison with neonates of normotensive mothers","volume":"135","author":"Oikonomou","year":"2019","journal-title":"Early Hum. Dev."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/20\/2429\/922923\/cs-2021-0643.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/20\/2429\/922923\/cs-2021-0643.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:19:45Z","timestamp":1638274785000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/135\/20\/2429\/229966\/Osteoprotegerin-regulates-vascular-function"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":47,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,10,29]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20210643","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10]]},"published":{"date-parts":[[2021,10]]}}}